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1. List of Abbreviations 
 
ADE   Adverse drug event 
 
BH   Dr. Balázs Hankó, Ph.D. 
 
DNA   Desoxyribonucleic acid 
 
JT   Johannes Thoma 
 
MTM   Medication therapy management 
 
PICOS Tool to specify study characteristics. Abbreviation for patients, 
interventions, comparison, outcomes and studies 
 
PMC    PubMed Central 
 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-
Analyses 
 
QoL   Quality of life 
 
RZ   Dr. Romána Zelkó, M. Sc., Ph. D., D.Sc. 
 




Inpatient care  Inpatient care refers to all the services provided by 
pharmacists in a hospital. 
 
Medium care Medium care describes various types of cancer care that 
occur within specific institutions and healthcare facilities, 
which constitute neither hospitals nor community 
pharmacies. 
 
Outpatient care  Outpatient care comprises pharmacists’ services neither in 
hospital nor other settings of health facility but only in 
community pharmacies or home care services. 
 
Community pharmacy  Public pharmacies; no restriction to town or countrified 
pharmacies 
 
Town pharmacy Pharmacy in a town with > 20000 inhabitants  
 





The past years cancer has become a globally snowballing problem, expands to the most 
common cause of premature death and disability and is expected to escalate simply due 
to the growth and aging of population (World health organization, 2017; American 
cancer society, 2017; World health organization 2012).  
 
The description cancer is derived from the phenotype of the animal shellfish which runs 
rampant with its fishing jars just as the blood vessel ramifications and metastases of the 
disease cancer. The disease cancer is characterized by a deficient coordination of 
somatic cells between growth, division and apoptosis. Additionally the repairing 
mechanisms are debilitated or not existent. Hence the replication of somatic cells is out 
of balance with the consequence of uncontrolled and unbroken cell division. 
Furthermore, many abnormal cancer cells are similar to healthy somatic cells. 
Therefore, our immune system is in many cases not able to identify and attack these 
cells in an efficient way. The tumour cells create new blood vessels by themselves 
which expand to the surrounding tissues and advance the proliferation.  
 
Down to the present date the oncology time bomb predicted in 1999 by an American 
Cancer Society task force has exploded (Fasola et al., 2008). There is no longer doubt 
about increasing incidence and prevalence of cancer. The disease cancer presents 
national healthcare systems around the world a dramatic challenge. Despite of scientific 
progress the disease cancer is still fatal for many patients In developed countries there is 
a high probability that death will occur either with warning as a result of chronic disease 
or malignancy (Sullivan et al., 2011). Coming from a nature death and looking around 
in relatedness or the circle of friends there are almost only two reasons for natural death 
– cancer or cardiovascular diseases such as cardiac infarction or insult. The number of 
deaths caused by cancer increases every year. Every year 3.2 million Europeans are 
diagnosed with cancer, a figure that is expected to rise (Sullivan et al., 2011).  
 
The discussion about possible reasons could fill out several separate dissertations. 
Public health initiatives and scientific advancements have us living longer and living 
and dying differently than in centuries past (Cortis et al., 2013). Patients receive more 
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treatments than ever before due to the increasing number of available agents (Mancini et 
al., 2012). The demographic development consequently leads to the absorption of 
greater amounts of noxious substances. Environmental and also nutritional conditions 
are changing none too in a positive way.  It is a natural procedure that our cells revolve 
permanently and it is just as common that cells sometimes convert to abnormal cells. 
Therefore, the human being owns natural repairing machineries. But the higher the 
amount of poisons and the longer the absorbing time period there is a growing risk to 
overstrain this system with the consequence of falling ill with cancer occurring in many 
cases with spreading metastases and finally ending in the death. A substantial 
proportion of the worldwide burden of cancer could be prevented through the 
application of existing cancer control knowledge and by implementing programs for 
tobacco control, vaccination (for liver and cervical cancers), early detection and 
treatment, as well as public health campaigns promoting physical activity and a 
healthier dietary intake (Jemal et al., 2011).  
 
Economic aspects will become an important parameter in future oncology care. (Fasola 
et al., 2008; Chastek et al., 2012; Schickedanz, 2010). The disease cancer is becoming a 
major economic expenditure and pushes national health systems to their personal and 
financial limits (Sullivan et al., 2011). Cost containment strategies are required to 
suppose the challenge of rising cancer diagnoses and oncology drug expenditure (Fasola 
et al., 2008). By now health care systems worldwide are faced with an ascending 
financial burden and a significant shortage of qualified oncology and hematology health 
care professionals by 2020 (Session et al., 2010; Hall et al., 2015). The diagnosis cancer 
often means little time left in the remaining life time of affected patients. It will take 
some time yet until certain types of cancer are no longer obligatory fatal. Therefore, the 
consensus from all groups concerned is that policy makers, politicians, patients, and 
health care professionals need to address the issue now (Thoma et al., 2016). Besides 
scientific progress, footraces to better and better drugs and promising therapeutic 
approaches one has to develop further ideas to limit this rapid emerging problem.  
 
The idea of this PhD thesis was triggered in my pharmacy by the daily contact with 
cancer patients appearing with prescriptions of highly effective drugs and in the same 
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manner insufficient knowledge about intake, effects and consequences. Patients felt 
unsafe with the handling and there was a great demand for consultancy. Therefore, in 
my mind from day to day the suggestion maturated that usage of pharmaceutical expert 
knowledge is urgently needed in oncology care.  
 
Hoppe – Tichy investigated that demand for pharmacy cancer services is expected to at 
least double over the next decade (Hoppe – Tichy et al., 2010). There is need for 
affordable and good follow-up care especially for patients without any cancer treatment 
due to irreversible progression of tumour (Slanska et al., 2013). Patients with cancer 
require special pharmaceutical care in terms of medication selection, dose calculation, 
and pharmacokinetic and pharmacodynamic considerations (cf. Tuffaha et al., 2012). 
Systemic therapies are part of most therapeutic algorithms and for some malignancies 
they even seem to be the only option (Liekweg et al., 2004). Therapeutic strategies for 
cancer patients are highly individualized and include a variety of drugs with different 
pharmacological mechanisms and targets (Liekweg et al., 2012).  
 
With their knowledge about drugs, pharmacists may be able to contribute in different 
ways to improve cancer care and complement the multidisciplinary cancer care team. 
Professionals could share the burden of care, and cross-border collaboration of expertise 
could be a major step toward increasing the survival and quality of life of cancer 
patients (Liekweg et al., 2004; Barth et al., 2009).  
 
Much effort and research have been presented over the past years about the future of 
practice of oncology (Session et al., 2010). Only few studies discussed the beneficial 
role of community pharmacists’ support in cancer care, such as provision of safe 
outpatient chemotherapy, assistance for home care patients or their positive influence on 
cancer patients’ quality of life (Takagi et al., 2011; Satoh et al., 2014; Katori et al., 





In my PhD thesis I analysed the use of community pharmacists’ in present cancer care 
of Hungary and Germany. My target was to focus on the analysis of the following 
questions:  
 
What is quantity and utility of outpatient models of pharmaceutical cancer care 
compared to existing interventions of pharmacists in hospital or ambulatory oncology 
settings? 
 
Is there need for community pharmacists in the daily reality of cancer patients in 
Hungary and Germany? 
 
What is the opinion of health experts regarding the use of community pharmacists in 





4.1 Literature research  
I performed broad literature research to get an overview of existing models of 
pharmaceutical care in oncology. I focused on outpatient models of pharmacists’ 
interventions and compared them with models in hospitals or ambulatory settings. 
Thereby I received a picture of quantity and utility of community pharmacists’ 
interventions in literature. I summarized my findings in a systematic review. 
 
To perform PubMed database research I developed key questions, which seemed highly 
appropriate to the topic - quantity and quality of community pharmacists’ interventions 
in oncology care. 
 
The following 4 key questions were posed according to the “PICO” tool:What models 
of pharmacists’ interventions exist in oncology care? 
  
1. What beneficial outcomes of existing pharmacists’ interventions in oncology 
care are reported? 
2. Are there trials that consider the efficacy of pharmacists’ interventions in 
oncology care? 
3. Is there a disparity in quantity of scientific research between outpatient 
approaches of pharmacists’ interventions and existing models in inpatient and 
medium oncology care? 
 
4.1.1 Search  
 
On basis of mentioned key questions I built 4 groups of key words. With the objective 
to hit all relevant contents preferably efficient database research was performed with 
several combinations of these key words, which produced studies containing 




I used the following key words: 
 cancer – carcinoma – oncology  
 service – intervention – model – program – approach – setting – management – role 
 pharmacist – patient – hospital – community – inpatient – outpatient – clinic – team 
– support – care – assistance 
 cost – mental health – quality of life – efficiency – adverse drug reactions – drug 
interactions – complementary therapy – nutrition – palliative – symptom – pain – 
home   
 
I combined two to four key words using the “and” connector to limit the number of 
irrelevant papers. To increase the likelihood of relevant hits I used diverse forms of 
single key words, such as pharmacist, pharmacy, and pharmaceutical. The combinations 
of search terms were determined by consensus of the investigators Johannes Thoma 
(JT),  Romána Zelkó (RZ) and Balázs Hankó (BH). To reach diverse subject areas, I 
also used the “or” connector with many of the combined terms. I used the PubMed 
Central (PMC) advanced search builder and restricted searches on titles and abstracts to 
avoid accumulating nonessential papers. An example search strategy is included in the 




The first electronic database search was performed on 26 November, 2013, in PubMed 
Central (PMC) to identify relevant information for addressing the main question. On 12 
July, 2015, I specified concise search terms and performed an updated search to refresh 
our data pool. To identify studies that were missed by the electronic literature searches, 
I also manually searched journals. Additionally, the reference lists of all the identified 
studies were checked for related articles. Original authors were not contacted for further 
information. To ensure a comprehensive inclusion of relevant papers, I used the 
University of Illinois research guide to conduct an additional search.  
DOI:10.14753/SE.2019.2307
11 
Study selection  
 
Screening and eligibility assessment was performed independently by the investigators. 
I reviewed the titles and abstracts to judge which ones included potentially relevant 
information. BH checked the titles and abstracts independently and RZ double-checked 
them. Any disagreement was resolved by consensus.  
 
Data collection process  
 
For data extraction I followed this same procedure to screen the full-text manuscripts, 
thereby applying the inclusion criteria to assess the validity of eligible trials. Through 
this process I determined which papers should be included in the systematic review. To 
keep track of the information pool it was necessary to structure the pool of information. 
Therefore, I allocated the received data to three clusters of care: inpatient, medium and 
outpatient. Admittedly a certain degree of subjectivity is not avoidable, but allocation 
was performed in all conscience and in consensus with all team members.  
 
On basis of the first three key questions I received information, what models and what 
outcomes of pharmacists’ intervention exist down to the present date and how effective 
pharmacists’ interventions contributed to oncology care. With these structured data it 
was possible to illustrate and to compare quantity and utility of pharmacists’ 
interventions in inpatient, medium and outpatient care. Thereby I was able to assess the 
fourth key question regarding the disparity between outpatient approaches of 
pharmacists’ interventions compared to inpatient and medium care. 
 
4.1.2 Eligibility criteria 
 
Inclusion and exclusion criteria were specified using the PICO tool in accordance with 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement. I defined selection criteria in terms of participants, types of intervention, 




4.1.3 Type of participants/problem 
 
Participants with any type of malignant disease were included in the study. Malignant 
disease is defined as any malignant growth or tumour caused by abnormal and 
uncontrolled cell division, which may spread to other parts of the body through the 
lymphatic system or the blood stream. There were no restrictions imposed based on age, 
race or sex. 
 
4.1.4 Type of intervention/comparison 
 
Studies discussing existing models of pharmaceutical interventions in inpatient, 
medium, and outpatient oncology care, that compared their results to those of standard 
care were included. That is, the outcomes of pharmacists’ interventions were compared 
with outcomes that occurred without pharmaceutical interventions. The terms 
“inpatient”, “medium”, and “outpatient” care are specified in chapter 3 - Data Items.  
 
4.1.5 Type of outcome measure 
 
I included studies reporting beneficial outcomes of pharmacists’ interventions in 
oncology care, such as cost reduction, improvement of social-mental health, and 
enhancement of a patient’s quality of life. Studies concerning reduction of adverse drug 
reactions and drug interactions, improved adherence to cancer therapies, and benefits of 
complementary therapies and nutritional support were also included. Finally, I included 
studies discussing the efficacy of pharmacists’ interventions in oncology medical 
practices. 
 
4.1.6 Type of studies 
 
I included only peer-reviewed studies reporting existing models of pharmaceutical 
interventions in inpatient, medium, and outpatient oncology care that were published 
between 26 November, 2003 and 26 November, 2013, and conducted a subsequent 
search on 12 July, 2015, to bring our available data up to date. I did not impose limits 
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based on type of article, length of follow up or text availability; if an abstract or full text 
was missing or deficient I performed a hand search to retrieve the desired data. Finally, 
no language restrictions were imposed — foreign language texts were translated. 
Choosing only those studies that met the inclusion criteria, and without restricting the 
type of article I built a comprehensive analysis. 
4.1.7 Review Protocol  
 
The above mentioned methods of the literature analysis were documented in the 
following review protocol. 
 
My Background was the occurrence of cancer patients in my own pharmacy with 
insufficient knowledge about intake and effects of anticancer drugs. Therefore, I posed 
the review question as follows: Is it necessary to further investigate quantity and utility 
of community pharmacists’ interventions in oncology outpatient assistance? 
 
Subsequently I created 4 key questions with the objective of comparing community 
pharmacists’ approaches in outpatient care and interventions in inpatient and 
ambulatory care. 
 What models exist in literature? 
 What outcomes exist in literature? 
 Are pharmacists’ interventions efficient? 
 Is there a disparity in quantity of scientific research regarding 
outpatient models of pharmacists’ interventions and models in 
inpatient or medium care? 
 
I defined inclusion criteria according to the PICOS tool. There was no restriction 
regarding the language of the analysed literature. If necessary, translation was 
performed. I only included peer reviewed studies. To maintain comprehensiveness there 




Precondition for the inclusion of studies was the reporting on cancer patients. I only 
included studies discussing pharmacists’ interventions in cancer care however formed. 
Subsequently I used studies comparing the results of pharmacists’ intervention with 
standard care. This means the results of pharmacists’ intervention was compared with 
the result occurred without pharmaceutical intervention. Referring to the outcome 
measure of the studies I focused on items such as drug interactions, cancer patients’ 
quality of life, nutritional support, pain management, social – mental health or cost 
reduction. 
 
Literature search was based on the information sources PubMed and University of 
Illinois research guide. With the objective of maximizing the data pool and receiving 
comprehensive results it was important for me to use two databases for my research. 
PubMed database was used for the main research. Afterwards the University of Illinois 
research guide was used for checking the PubMed database search terms for coherency 
and completeness.  declared key words based on PICOS oriented key questions and 
classified them in 4 groups. Then I combined key words from each group to receive data 
preferably pertinent to the key questions. 
Study selection was performed by reviewing titles and abstracts and then full text 
screening with application of inclusion criteria. The study selection was checked by 
three team members, independently from each other. The same procedure was exercised 
to extract the study data. The detailed process of study selection and data extraction is 
illustrated in 6.1.1. 
 
With the objective of ensuring quality I appraised the quality of each individual study, 
took care of publication bias and selective outcome bias as illustrated in 6.1.8. 
 
Data synthesis was performed by the allocation of received data to inpatient, medium 
and outpatient care. Subsequently I compared and estimated the results of scientific 
research concerning quantity and utility of community pharmacists’ interventions. 
 
Finally, I published the review in the International Journal of Clinical Pharmacy. I 
distributed a questionnaire in Hungary and Germany and analysed a potential 
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correlation of community pharmacists’ interventions in literature and patients’ needs in 
cancer reality. 
 
On 12 July, 2015 I performed an update research and modified my original results. 
Almost 2 years after the first research my objective was to refresh the data pool and to 
avoid missing studies. Therefore, I performed the same research procedure and 
additionally tried to bring the search terms into a sharper focus. Thereby I was able to 
include studies published in the meantime since the first research. With the knowledge 
of the original data pool it was possible to search the received titles and abstracts 
systematic for missing content. As in the first research process the procedure was 
performed for the PubMed database and the Illinois research guide as well.  
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Synthesis of results: 
 
     PubMed Central 
 




Study selection:    ▼ review of titles and manuscript,                                 
           double check   
 
     220 papers 
▼ full text analysis, 
application ofinclusion criteria 
 
68 papers 
Data collection:    ▼ inclusion in systematic review 
 
Models, outcomes and efficacy of pharmacists’ interventions 
 
      ▼ allocation 
 
 Outpatient care   Inpatient care  Medium care
   
Comparison of outpatient approaches and inpatient and medium approaches 
 
Response of 4 th key question 
     ▼ 
Main questions response 
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Example search strategy:  
 
cancer and review and service and pharmacist 
or 
cancer and intervention and pharmacist and pain 
or 
cancer and intervention and pharmacy and pain 
or 
oncology and service and community and pharmacist 
or 
oncology and pharmacist and service and outpatient 
or 
oncology and pharmacist and service and hospital 
or 
oncology and pharmacist and quality of life 
 
4.1.8 Assessment of risks of bias 
 
Validity of each individual study was confirmed by assessing the risks of bias on study 
and outcome level of all trials elected for review inclusion. Therefore, I appraised 
randomization and adequacy of allocation concealment as well as methods used to 
receive outcomes of individual studies. BH checked my findings. Besides bias in each 
individual study I also considered risks of bias across studies. I cannot obviate that there 
may be appropriate but missing studies. With the very broad and systemic search 
procedure I tried to reduce this risk of publication bias to the smallest possible level. In 
addition I tried to decrease the possibility of a one sided outcome reporting bias with a 
three person containing data collection process to a preferably small degree. 
Nevertheless, one has to be aware of these different scopes of occurring bias when 
interpreting the investigated results. 
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4.2 Questionnaire analysis 
 
A self developed questionnaire was distributed to cancer patients in hospitals and 
pharmacies of Hungary and Germany to analyse cancer patients’ attributes and their 
preferences regarding community pharmacists and cancer linked topics. Statistical 
evaluation of returned questionnaires provided an image of cancer patients’ reality 
needs 
 
The questionnaire consisted of 22 closed - ended questions and one open question in the 
end. I considered, which information seemed to be important to analyze current status 
quo in cancer care of both countries and how to explore patients’ preferences and 
expectations from community pharmacists. Based on these thoughts questions with the 
target of receiving preferably comprehensive information were contrived.  
 
I performed a tripartite validation procedure. The prepared questionnaire firstly was 
checked by BH, secondly by RZ and thirdly by five physicians. My objective was to 
avoid inappropriate questions or ambiguity and maintain validity, suitability and 
comprehensibility. It was a conscious decision to choose five health experts and not the 
target group for the questionnaire validation. I accurately deliberated whether it was 
constructive to ask health experts or the targeted patient group. Both groups show 
benefits and disadvantages. Physicians certainly can assume the questionnaire from the 
medical and technical perspective. But in comparison to cancer patients’ physicians 
probably aren’t able to put themselves into patients’ physical and emotional atmosphere. 
The targeted patient group certainly is able to examine the comprehensiveness from the 
perspective of an ordinary person in a better way than physicians.  
 
Both groups include the hazard of false positive results. On the one hand physicians 
could imagine that the task is clear anyway - no need for occupation with the 
questionnaire in an intense way. On the other hand the targeted patient group could be 
ashamed of admitting that they do not understand parts of the questionnaire. The main 
factor deciding against the targeted patient group was the knowledge of a sensitive 
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patient pool in exceptional circumstances with extraordinary physical and psychical 
strains. 
With the knowledge of the benefits and disadvantages of both groups finally the ethical 
conscience predominated and I decided to ask the physicians for questionnaire 
validation to avoid unnecessary stress for the targeted patient group. 
 
The validation of a questionnaire distributed in two countries also requires comparable 
questionnaire versions in both countries. I consciously developed the questionnaire 
together with BH in English language. I translated the English version to German and 
BH to Hungarian. I assumed that the translation of the well established English 
language to the particular native languages is less fault-prone than the direct translation 
from German to Hungarian. Both developers of the questionnaire also were the 
translators to their particular native language.  Therefore, there is little likelihood of 
differences regarding the comparability of both versions and hence the obtained data. 
The level of comparability of both versions and the content identity of obtained data is 
comprehensible at anytime.  
 
The questionnaire was distributed in 26 community pharmacies and 4 hospitals in 
Hungary and Germany from August 2013 to October 2014. Pharmacy selection was 
performed by reflecting on proper questionnaire randomization. I primarily classified 
the questionnaire distribution places into hospitals and community pharmacies. Then the 
community pharmacies were classified in town- (inhabitants > 20000) and village 
pharmacies (inhabitants < 20000).  
 
The following distribution places were selected in Germany: 
 
“Pharmacy in Westpark” Ingolstadt   (town pharmacy) 
“Pharmacy in Hollis center” Ingolstadt   (town pharmacy) 
“Pharmacy Riem Arcaden” Munich   (town pharmacy) 
“Staren Pharmacy” Kelheim    (village pharmacy) 
„Adler Pharmacy“ Mitterfels    (village pharmacy) 
„Burg Pharmacy“ Kallmünz    (village pharmacy) 
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“Heilig-Kreuz Pharmacy Kelheim    (village pharmacy) 
„St. Georg Pharmacy“ Mitterfels    (village pharmacy) 
“Holzner Pharmacy” Bogen    (village pharmacy) 
“Sonnen Pharmacy” Burglengenfeld   (village pharmacy) 
„Barbara Pharmacy“ Maxhütte Haidhof   (village pharmacy) 
„St. Anna Pharmacy“ Riedenburg    (village pharmacy) 
“Hubertus Pharmacy” Bogen    (village pharmacy) 
 
St.Johsef hospital” Regensburg   (hospital) 
“University hospital” Regensburg    (hospital) 
 
The following distribution places were selected in Hungary: 
 
Mikszáth Pharmacy, Budapest    (town pharmacy) 
Kútvölgyi Pharmacy, Budapest    (town pharmacy) 
Szent Rókus Pharmacy, Miskolc    (town pharmacy) 
Mária Pharmacy, Miskolc     (town pharmacy) 
Patika Libra Pharmacy, Dunaújváros   (town pharmacy) 
Patika 52 Pharmacy, Rácalmás    (village pharmacy) 
Tölgyfa Pharmacy, Kerepes    (village pharmacy) 
Szilasliget Pharmacy, Szilasliget    (village pharmacy) 
Oroszlán Pharmacy, Szerencs    (village pharmacy) 
Szent Miklós Pharmacy, Kunszentmiklós   (village pharmacy) 
Magyar Korona Pharmacy, Kunszentmiklós  (village pharmacy) 
Szent György Pharmacy, Kecel    (village pharmacy) 
Kossuth Lajos Pharmacy, Apostag    (village pharamcy) 
 
Semmelweis Egyetem , 1st Department of Internal Medicine (hospital) 
Semmelweis Egyetem, 3rd Department of Internal Medicine (hospital) 
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On the one hand, I tried to manage the distribution in a way that approximately equal 
numbers of valid questionnaires could be received in community pharmacies and 
hospitals. On the other hand the intention was to receive approximately equal numbers 
of questionnaires in town and village pharmacies. Therefore, I assumed the 
characteristic patient flow of town and village pharmacies according to rational 
consideration. Accurate numbers of patient flow are difficult to receive, apply to the 
company secret and only few pharmacy owners would be willing to relinquish these 
sensitive data. In both countries there is a general trend that young people move to 
major towns and their parents and grandparents remain in the villages accompanying a 
lower average age in towns.  
 
Major towns offer a magnitude of important factors for young people. There may be 
universities allowing academic studies or broader possibilities to enjoy the off time. 
Accordingly, in towns there often is a higher amount of active working population and 
consecutively superior spending power. Against this background the expectation was to 
deal in town pharmacies with an increased patient flow and consecutively with 
increased rates of questionnaire return compared to village pharmacies. Hence 
approximately triply village pharmacies were provided with questionnaires compared to 
the number of town pharmacies. Targeting valid and representative results there was a 
statistical calculation before questionnaire distribution referring to the required number 
of questionnaires. Presuming a confidence interval of 95% and a maximal tolerable 
sample error of 10%, the intention was to receive at least 100 questionnaires for 
evaluation. It was calculated with a basic population of 1,000,000 patients. 
 
Due to the sensitive patient pool 25 % rate of response was calculated; Response rate 
was calculated by searching for a preferably comparable reference point and applying 
individual criteria of questionnaire composition, distribution proportions and target 
group attributes. Iversen et al. received in 2012 a questionnaire response rate of 52 % 
(Iversen et al., 2012). At the time of questionnaire distribution this reference was quite 
recent and exhibited similar setting conditions such as a paper based survey, 
questionnaire development based on the findings of a literature review, cancer patients’ 
assessment of hospital care, cancer patients suffering from all kinds of cancer and 
DOI:10.14753/SE.2019.2307
22 
questionnaire distribution in inpatient and outpatient clinics. Our questionnaire 
comprised 9 pages and addressed a sensitive target group in extraordinary 
circumstances. It is known that the response rate decreases with increasing page number 
and sensitivity of the target group. The questionnaire was not mailed but distributed at 
the local distribution places. Therefore the target group did not receive the questionnaire 
directly. In each case of distribution there was either pharmacy or hospital staff between 
author and target group.  
 
The success of questionnaire distribution on the one hand largely depends on addressing 
the target group. Hence the level of staff motivation is essential. There were no 
monetary or other incentives either for the patients or for the staff. The questionnaires 
were handed out to one crew member. Hence there is the obstacle of information 
transfer to the residual crew members. Just in bigger hospitals or pharmacies there is the 
risk of confusion and questionnaire loss. Additionally there is the fact of crew changes. 
In the worst case the crew member the questionnaires handed out to had left the 
pharmacy two weeks later accompanying the loss of all distribution information. 
Furthermore the long list of agents with oncology indication as inclusion criteria 
exhibits the drug names. In many cases prescriptions only contain the trade names of the 
product. The mental transfer to pull trade name and inclusion criteria together and 
subsequently to address the target patient is a further obstacle restricting the response 
rate.  
 
All above mentioned issues the author wasn’t able to influence. Finally the entire 
comparison of Iversen et al.’s reference and my distributed questionnaire is difficult. 
Considering above mentioned points and the authors’ intention to calculate the response 
rate carefully a response rate of 25 % was assessed suitable. 
 
Hence 400 questionnaires were intended for distribution. To avoid bias and to achieve 
proper randomization, the distribution points of questionnaires were elected in all 
cardinal directions in the surroundings of Budapest in Hungary and Regensburg in 
Germany and deliberately excluded pharmacies within a radius of 5 km to oncologists. 
Without this condition there could have been for example 100 questionnaires from one 
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pharmacy next to an oncologist due to the convenient clientele visiting this pharmacy 
frequently. Subsequently this condition was necessary to ensure the objective of equal 
numbers of questionnaires in town and village pharmacies.  
If the pharmacy or hospital agreed we left 10 - 15 questionnaires at each distribution 
place. The questionnaires were delivered face to face at the particular distribution 
places. The procedure was continued up to the distribution of 400 questionnaires. 234 
questionnaires were distributed in Germany and 180 in Hungary making a total of 414. 
Finally, 73 questionnaires were received in hospitals, 40 questionnaires in town 
pharmacies and 35 questionnaires in village pharmacies, making a total of 148. 
 
Patients were screened by hospital and pharmacy staff by application of inclusion and 
exclusion criteria and were informed about the aim of the study. Pharmacy and hospital 
staff was not allowed to help the patients if any question came up. The questionnaire 
was voluntary and anonymous. Participants could decide if they wanted to answer 
directly in the pharmacy, hospital or at home. The involvement of the patients was 
diverging and mostly dependent on the physical constitution of the particular patients. 
End stage cancer patients were rarely in the mood for answering the questionnaire. 
Questionnaires answered at home then returned to the particular distribution place. After 
a few months all filled questionnaires were collected personally from the particular 
distribution places. Data handling occurred in accordance with the law of Hungary and 
Germany.  
 
4.2.1 Inclusion criteria  
 
Voluntary patients were only asked to answer the questionnaire, if they were treated 
with an anticancer drug, which was mentioned in a defined list. I developed this list and 
submitted it to BH and RZ for checking. The list included all prescription drugs in 
German market containing an oncology indication up to the time of distribution in 
August 2013 and is attached in Appendix in the end of the original questionnaire. 
Interview partners were elected if they verified their professional license and agreed to 





If patients were not able to answer the questionnaire due to physical or psychical 
restrictions, they were excluded from the study. Patients who were reluctant to answer 
were also excluded. 
 
4.2.2 Evaluation/ Statistical methods  
 
Statistical evaluation was performed by descriptive analysis. The statistical software and 
expert knowledge was provided by Andrea Meskó – Semmelweis University Budapest. 
If patients provided a rating on a scale analysis was performed by means of measure of 
central tendency and determination of standard deviation. The significance of 
differences among groups was evaluated with Bonferroni test. The level of significance 
was defined a priori at 5 %. Chi square test was used for categorical variables, Fischer 
exact test for border values. The one-sample Kolmogorov–Smirnov test method was 
used to identify the kind of distribution in two groups. The Mann–Whitney and 
Wilcoxon W-test methods were used to analyze group differences in the mean of an 
examined parameter. 
 
4.2.3  Survey 
 
The first part of questionnaire was aimed at investigating quite general questions, such 
as gender, age, the level of education, type of cancer or location, where the 
questionnaire has been received. The second part was targeted at evaluating patients’ 
life style conditions such as smoking and collecting a picture of patients’ attitude to 
cancer linked topics, such as information points, adverse drug reactions, reception of 
food supplements or mental support and assessment of pain or QoL. In the end patients 
had the possibility to state their wishes and expectations from community pharmacists 
to lift cancer patients QoL in future oncology care. The original questionnaire is 




Our research is in compliance with the 1964 Helsinki declaration and its latter 
amendments or comparable ethical standards. There is no ethics committee approval 
because this study is based on a questionnaire survey with anonymous and voluntary 
participation. Due to the anonymous questionnaire survey there is no signing of 
informed consent. Instead the aim of the study was written at the top of the 
questionnaire and the purpose of this study was explained accurately to all volunteers 
orally. 
 
4.3 Interview of professional health experts 
I completed my image of pharmacists’ contributions in oncology care by asking health 
experts about possible supportive interventions, main obstacles and solution approaches 
to cross these obstacles in future.  
 
To amplify the information pool for assessment of community pharmacists’ use in 
present cancer care the process of opinion making was finalized by asking five 
practicing oncologists and five community pharmacists to give their opinion to four self 
developed questions. I called oncologists and pharmacists in the surroundings of 
Regensburg and explained my project in detail. In case of agreement I made an 
appointment and visited the interview partners at their workplace in Germany. After 
exhibiting the job license I conducted the interviews in a relaxed face to face 
atmosphere. I tried to create questions, which permitted reception of preferably 
comprehensive answers to achieve a diversified picture of community pharmacists’ 
support in cancer care. These questions were likewise checked by BH and RZ.  A 
provident check for validity was performed in the same manner as aforementioned.  
 
Professional health experts were asked to consider possible supportive interventions of 
pharmacists in oncology care, advantages for patients, main obstacles and solution 
approaches to cross these obstacles in future. Professional health experts were accepted 
as interview partners if they were able to exhibit their job license. Analysis was 




After literature research and the evaluation of cancer patients’ questionnaire these 
expert assessments were the last brick of three information sources to complete 
comprehensive opinion formation for the assessment of community pharmacists’ use in 
present cancer care of Hungary and Germany. Interviews were performed on the basis 





5.1 Results of literature analysis – Models and outcomes of pharmacists’ 
interventions in cancer care 
The primary outcome measure was to estimate the quantity and utility of pharmacists’ 
interventions in outpatient oncology care compared to inpatient and medium care. 
Literature searches identified 2470 papers. A review of those titles and abstracts 
retained 220 manuscripts for detailed analysis, on which full-text analysis was 
performed. After subsequent application of inclusion criteria, 68 papers remained, 
which were included in systematic review. 
 
5.1.1 Inpatient care: Models, outcomes and efficiency of pharmacists’ interventions 
 
Several studies have investigated the importance of pharmacists providing direct patient 
care and patient education in oncology care including medication therapy management 
(MTM) (Schickedanz 2010; Ise et al., 2014; Avery et al., 2015); Döhler et al., 2011; 
Yeoh et al., 2013). For example, on a given clinic visit, the pharmacist enters the room 
with the primary nurse and goes through the medication containers the patient has 
brought in [Cortis et al., 2013; Voll et al., 2010). This is in keeping with Swedish 
pharmacists, who work as members of the health care team and participate in medical 
rounds in the mornings together with physicians, nurses, and assistant nurses (Bremberg 
et al., 2006). Several studies discussed that patients seem to benefit from pharmaceutical 
care, as indicated by patients’ self-reported outcomes such as reduced emetic episodes, 
improved quality of life, and satisfaction following implementation (Liekweg et al., 
2012; Kawaguchi et al., 2012; McKee et al., 2011; Ibrahim et al., 2013; Silpakit et al., 
2006).  
 
Indeed, the significant role of clinical pharmacists with their understanding of medical 
practises in oncology settings has been published in reports, who claim that this team 
work benefits both oncologists and pharmacists and allows oncologists to focus on 
disease eradication as shown by Bremberg et al. (Bremberg et al., 2006). There are many 
studies of clinical pharmacy services showing that pharmacists contribute to safer 
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medication use, to the prevention and reduction of adverse drug reactions and 
interactions, to enhanced medication adherence, and to a continuum of oncology care 
(Liekweg et al., 2004; Ibrahim et al., 2013;  Touchette et al., 2014; Leveque et al., 2014; 
Delpeuch et al., 2015; Khanal et al., 2010; Walter et al., 2014; Felton et al., 2014; 
Coutsouvelis et al., 2010; Katayama et al., 2006; Tuffaha et al., 2006; Inoue et al., 2004; 
Chan et al., 2009). 
 
The importance of pharmacists that own a variety of clinical services in mental health 
care is also starting to be recognised around the world (Arunachalam et al., 2011; 
Richardson et al., 2014). Richardson et al., for example, indicated that implementing 
clinical pharmacy services in inpatient mental health has significant potential for 
improving economic, clinical, and humanistic outcomes for patients and for the mental 
health system (Richardson et al., 2014).  
 
Pharmacists can also contribute to cost-reduction and a good cost-benefit ratio in 
palliative care settings (Bremberg et al., 2006; Norrström et al., 2010). Interestingly, 
other clinical fields have already demonstrated the benefits for patients receiving 
nutritional support or complementary therapy options (Tuffaha et al., 2012; Mousavi et 
al., 2013). Mousavi et al., for example, found that a clinical pharmacist-based nutrition 
support service significantly improved the nutritional status and clinical outcomes of 
bone marrow transplant patients (cf. Mousavi et al., 2013). Moreover, patients report 
significantly increased satisfaction after receiving MTM (Yeoh et al., 2013). The 
inclusion of pharmacists in the pain and symptom control clinic is favoured by patients 
and health care professionals, and provides increased efficiency to the clinic (Ryan et 
al., 2012).  
 
5.1.2 Medium care: Models, outcomes and efficiency of pharmacists’ interventions 
 
There are several approaches that reflect an expanding role of pharmacists in the care of 
cancer patients in specialised settings (Shah et al., 2006; Valgus et al., 2011; Ruder et 
al., 2011; Chew et al., 2015; Van den Broucke et al., 2014; Ishimoto et al., 2004; 
Koshita et al., 2007). Supportive care in outpatient chemotherapy clinical centres, and 
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specialised cytostatic compounding pharmacies are just a few examples. Another 
example can be found in Japan, where the shortage of drugs available to physicians in 
hospitals has stimulated the creation of teams by medical institutions, to meet the needs 
of an increasing number of cancer patients (cf. Iihara et al., 2012). Moreover, there are 
an ascending number of models following the paradigm shift from a disease-focused 
towards a patient-focused, safe, effective and convenient approach [cf. Tuffaha et al., 
2012; Liekweg et al., 2004).  
 
Furthermore, pharmacists in the British Columbia Cancer Agency are often called on to 
advise patients on the use of complementary therapy such as herbs and dietary 
supplements (cf. Paul et al., 2013; Lemos et al., 2005). Pharmacy counselling services in 
an outpatient chemotherapy clinic are vital to a patient’s understanding of their 
chemotherapy and supportive medication (cf. Ibrahim et al., 2013).
 First experiences 
show that patients fully agree with these pharmaceutical offers and may be willing to 
pay for pharmacy counselling services (cf. Ibrahim et al., 2013). Provision of drug 
therapy management, identification and reduction of drug-related problems, and 
prevention of drug interactions were reported as beneficial outcomes of pharmacists’ 
interventions as shown by Tuffaha et al. (Tuffaha et al., 2012; Smith et al., 2014; 
Edwards et al., 2014; Lopez-Martin et al., 2014). Clinical pharmacists’ contributions to 
palliative care, moreover, include patient benefits such as improved symptom control, 
satisfaction of patients and families and finally possibly longer survival with improved 
quality of life (Tuffaha et al., 2012; Atayee et al., 2008; Shamie et al., 2013; Gagnon et 
al., 2012). Similarly, Iihara et al. showed how pharmacists contributed to the increased 
efficacy of medical practises by reducing physicians’ workloads (Iihara et al., 2012).  
 
5.1.3 Outpatient care: Models, outcomes and efficiency of pharmacists’ interventions 
 
Patient-centred home care is a new model of assistance. It is based on patients’ needs 
rather than on prognoses and takes into account the emotional and psychosocial aspects 
of the disease (cf. Tralongo et al., 2011).
 It is significant that several studies — 
especially in the field of outpatient palliative care — that have investigated the 
educational needs of pharmacists, have suggested that home palliative care offers ways 
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to integrate pharmacists into cancer pain management (Tralongo et al., 2011; Tait et al., 
2013; O’Connor et al., 2013; Kato et al., 2011; Hussainy et al., 2006; Akai et al., 2009; 
Hussainy et al., 2010; Savage et al., 2013; O’Connor et al., 2011). However, few studies 
discuss collaboration approaches between community pharmacists and hospitals (Takagi 
et al., 2011; Satoh et al., 2014; Katori et al., 2007). There are studies — mainly in Japan 
— concentrating on pharmacists’ assessments of outpatients (Suzuki et al., 2010). 
According to Needham et al., pharmacists visit patients at home to help them learn how 
to properly take their medications and to measure correct dosages.  
 
In view of this, community pharmacists have begun sharing information about their 
patients through care conferences attended by doctors from clinics and nurses from 
visiting nursing stations (cf. Needham et al., 2002).. The authors also describe how 
pharmacists provide information about prescribed drugs to the wives and daughters of 
patients who were in the end stages of cancer (Needham et al., 2002). Two Japanese 
studies suggested that the participation of a community pharmacist in palliative care is 
essential for patients and medical team members managing the extensive requirements 
associated with cancer pain (Kato et al., 2011; Akai et al., 2009). Additionally, Tralongo 
and colleagues found in an Irish context that home care reduced costs for patients by 
two-thirds compared with hospital care (Tralongo et al., 2011). Researchers describe the 
efficacy of pharmacists’ interventions in cancer pain therapy, evidenced in improved 
efficiency of opioid treatment based on the recommendations of a community 
pharmacists’ palliative care team (Needham et al., 2002).  Finally, the results of 
literature research are illustrated in Table 1. 
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Table 1 Outcome of pharmacists’ intervention in inpatient, medium and outpatient 
oncology care (Thoma et al., 2016). Pharmacists’ interventions were beneficial and have 
proofed efficacy in all three fields of pharmaceutical care. 
 
type of care outcome of interventions significance references 
    
inpatient care Improved quality of life  18, 32-34 
    
 improved nutritional status yes 49 
    
 patient satisfaction after receiving MTM yes 29 
    
 safe medication use,    
 enhanced medication adherence  
17, 33, 35-
45 
    
 cost reduction for health care systems  31, 48 
    
 
oncologists can focus on disease 
eradication  34 
    
medium care reduction of physicians workload  58 
    
 Improved understanding,    
 patients agree with counseling services  33 
    
 improved drug therapy management  16, 61-63 
    
 
improved syptom control in palliative 
care,    
 enhanced QoL  16, 64-66 
    
outpatient care home care reduced costs of national   
 health care systems  67 
    
 essential support of medical team    
 members in pain therapy  70, 72 
    
 home education leads to better    
 Understanding and correct intake  80 
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5.2 Results of questionnaire analysis 
 
From the 180 in Hungary and 234 in Germany distributed questionnaires, 62 Hungarian 
and 86 German questionnaires returned. Hence in total 148 questionnaires were 
evaluable. 
 
5.2.1 General results referring to basic attributes of the examined patient group 
53 (35.8 %) of the 148 patients were men and 95 (64.2 %) women. The predominating 
age of cancer patients (41.9 %) was between 61 and 75 years as shown in Figure 1. 10.1 

















Figure 1 Age distribution of the examined cancer patient population (Thoma et al., 2018). 
The predominating age of cancer patients is between 61 and 75 years. 
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There was significant difference in age (p=0.009) of Hungarian and German 
participants. In Hungary 39.3 % of the asked patients were between 61 and 75 years old 
and in Germany 42.5 %. In Germany there was excess of patients older than 75 (11.0 



















Figure 2 Age distribution of examined Hungarian and German cancer patients (Thoma et 






The findings also showed significant difference regarding gender (p=0.002) between 
Hungarian and German cancer patients as illustrated in Figure 3. In Germany women 
(74.4 %) predominated, in Hungary quantity of male and female participants was equal 

















Figure 3 Gender distribution of examined Hungarian and German cancer patients. (Thoma 
et al., 2018). In Hungary ratio of male and female patients was equal, in Germany 




According to the questionnaire breast (32.4 %) and bowel cancer (23.0 %) were the 
most common cancer types, which is illustrated in Figure 4.  This result has to be 












Figure 4 Partition of cancer types in the patient population (Thoma et al., 2018). The 
predominating cancer types were breast- and bowel cancer. 
DOI:10.14753/SE.2019.2307
36 
The results also indicated significant difference (p<0.001) between Hungary and 
Germany in most common cancer type. In Hungary bowel cancer (51.6 %) occurred 
most frequently, whereas in Germany breast cancer (46.5 %) and prostate cancer (12.8 
%) were the most common types as illustrated in Figure 5. This result has to be assessed 















Figure 5 Partition of cancer types in Hungary and Germany (Thoma et al., 2018). In 




Figure 6 illustrates that 64.2 % of the patients were diagnosed with cancer not longer 















Figure 6 Time period since patients in examined patient population were diagnosed with 
cancer the first time (Thoma et al., 2018). An Excess of cancer patietns was diagnosed 




From the 62 Hungarian questionnaires 44 (71.0 %) were received in hospital, 11 (17.7 
%) in town pharmacies and 7 (11.3 %) in village pharmacies. From the 86 German 
questionnaires 29 (33.7 %) questionnaires were received in hospitals, 29 (33.7 %) in 
town pharmacies and 28 (32.6 %) from village pharmacies. Above mentioned issues are 
illustrated in Table 2. 
 
Table 2 Questionnaire distribution place (Thoma et al., 2018). In Hungary there was an 
excess of questionnaires received from hospital. In Germany reception of questionnaires 
was shared consistent. 
 
. n = 148 hospital town pharmacy 
village 
pharmacy 
     
Hungary 62 44 (71.0 %) 11 (17.7 %) 7 (11.3 %) 
Germany 86 29 (33.7 %) 29 (33.7 %) 28 (32.6 %) 
 
 
Table 3 indicates that one third of cancer patients were smokers (33.8 %) and two third 
non - smokers (64.9 %). 
 
Table 3 Ratio of smokers and non - smokers in the patient population (Thoma et al., 
2018). Two third of cancer patients were non-smoker. 
 
frequency smoker non - smoker 
don't want to 
answer missing 
          
N = 148  
50 (33.8 
%) 96 (64.9 %) 1 (0.7 %) 1 (0.7 %) 
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5.2.2 Results referring cancer patients attitude to community pharmacists and cancer 
linked topics 
 
On a non percentage scale from 1 to 5 patients, who wanted information about cancer, 
chose significantly more often pharmacists (4.11 ± 1.11) and similar practitioners (4.33 
± 0.8) than website information (3.24 ± 1.68), social communication (3.06 ± 1.46) or 
television services (2.8 ± 1.45) as first information point. These findings are illustrated 





















Figure 7 Cancer patients’ expectations to get general information about cancer. Mean and 
standard deviation are illustrated (Thoma et al., 2018). On a non - percentage scale from 




Table 4 shows the significant difference (p<0.001) in seriousness assessment of internet 
information (4.38 ± 2.32) and information in community pharmacies (8.23 ± 1.81).  
 
Table 4 Seriousness assessment of cancer patients referring internet and pharmacy 
information (Thoma et al., 2018). On a non - percentage scale from 1 to 10 cancer 
patients assessed pharmacists’ information by far more serious than internet 
information. 
 
location seriousness assessment 
confidence 
interval significance p value c,d 
     
 
information valid Mean 
± SD 95% CI yes <0.001 
     
pharmacies n 
=114 8.23 ± 1.81 7.88 - 8.55   
     
internet n =120 4.38 ± 2.32 3.99 - 4.81   
     
c Statistical evaluation by means of "measures of central tendency" and determination 
of SD 
d Nonparametric bootstrap procedure used to obtain 
95% CIs.   
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Figure 8 illustrates that on a non percentage scale cancer patients assessed the validity 
of the information points pharmacist (8.23 ± 1.81), practitioner (8.44 ± 1.54) and 
oncologist (9.5 ± 0.83) more valid compared to information from the family (5.03 ± 
2.11), internet information (4.38 ± 2.32) and information in the neighborhood (3.28 ± 
1.64). Television information (3.82 ± 1.63) and information from friends (4.28 ± 1.64) 


















Figure 8 Assessment of cancer patients referring the validity of information points. Mean 
and standard deviation are illustrated (Thoma et al., 2018). On a non - percentage scale 




48.6 % of the asked population took pain killers and 39.2 % stated to have difficulties 
with the right dosage of their pain killers, as shown in Figure 9.  
 
 
Figure 9 Cancer patients’ assessment regarding pain killer use and the coordination of 
right pain killer dosage (Thoma et al., 2018). About half of the cancer patients took pain 




There was significant difference (p=0.012) in coordination of pain level and adequate 
intake of pain killers between hospitalized patients and patients in community 
pharmacies. Table 5 shows that pain management in hospital was better. I hospitals 52.3 
% of the patients were able to coordinate pain level and adequate intake of pain killers. 
In town pharmacies 20.0 % were able to do so, in village pharmacies 43.8 %. 
 
Table 5 Coordination of current pain level and adequate intake of pain killers in the 
examined patient population (Thoma et al., 2018). Hospitalized patients had better 
coordination of pain level and pain killer intake compared to cancer patients in 
community pharmacies. 
 
location coordination . significance p value a,b 
     
 yes no yes 0.012 
     
hospital n=44 23 (52.3%) 21 (47.7%)   
     
town pharmacy n=35 7 (20.0%) 28 (80.0%)   
     
village pharmacy 
n=16 7 (43.8%) 9 (56.2%)   
     
a Evaluation with Bonferroni test method. Chi square test was used for categorical 
variables.  
Fischer exact test was used for border values.   
b P value <0.05.     
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48.6 % of the patients were able to assess their pain level, whereas 79.1 % of cancer 




Figure 10 Ability of cancer patients to estimate their pain level and level of quality of life 
(Thoma et al., 2018). On a scale from 1 to 100 about three-fourths of cancer patients 
were able to estimate the level of quality of life. About half of the patients was able to 
estimate the pain level. 
 
On a scale of 1 to 100, cancer patients’ estimated level of QoL was 65.92 ± 19.25 in 
Hungary and 57.35 ± 23.45 in Germany. The evaluated median of estimated QoL 
differed in Hungary (70) and Germany (60). German data distribution was normally (p 
=0.62). Hungarian data were not normally distributed (p=0.046). The interquartile 
ranges (IQR) of both compared groups were 30.  Above mentioned results are illustrated 
in Tables 6 and 7 and published in Acta Poloniae Pharmaceutica – Drug Research 
(Thoma et al., 2018). 
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Table 6 Estimated level of quality of life of Hungarian cancer patients (Thoma et al., 
2018). On a non - percentage scale from 1 to 100 Hungarian cancer patients’ level of 
quality of life was at 65.92 ± 19.25. 
 
. Spalte2 statistic bootstrapb Spalte5 Spalte6 Spalte7 
   bias std. error 
95% confidence 
interval  
     lower upper 
n valid 49  6 38 60 
 missing 0 0 0 0 0 
mean  65.9184 -0.0215 2.7222 60 71.0701 
median  70 -0.26 3.0971 60 80 
mode  70,00a     
SD  19.2482 -0.18589 1.98193 15.24921 23.06492 
percentiles 25 50 1.615 4.4468 45 60 
 50 70 -0.26 3.0971 60 80 
 75 80 -0.245 2.0449 70 80 
a Multiple modes exist. The smallest value is shown.   
b Unless otherwise noted bootstrap results are based on 1000 bootstrap samples. 
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Table 7 Estimated level of quality of life of German cancer patients (Thoma et al., 
2018). On a non - percentage scale from 1 to 100 German cancer patients’ level of 
quality of life was at 57.35 ± 23.45. 
 
. .2 statistic 
bootstrap 
b .3 .4 .5 





     lower upper 
n valid 79  6 68 89 
 missing 0 0 0 0 0 
mean  57.3544 0.148 2.6455 52.1291 62.5 
median  60 1.28 4.3509 50 70 
mode  70     
SD  23.44609 -0.34246 1.48849 20.14988 25.97786 
percentiles 25 40 0.04 7.608 30 50 
 50 60 1.28 4.3509 50 70 
 75 70 3.5625 4.677 70 80 




68.2 % of the asked patients had experiences with adverse drug reactions over the time 
period of treatment. 8.8 % of the participants stated, they have never been informed 
about possible occurring adverse drug reactions, which is illustrated in Figure 11. 
 
 
Figure 11 Experience of cancer patients with adverse drug events and with received 
information about adverse drug events (Thoma et al., 2018). About two third of cancer 
patients had experiences with adverse drug events. About three-fourths of cancer 
patients received information about adverse drug events. 
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Table 8 illustrates that 46.6 % of the patients indicated to expect more information 
about nausea as possible adverse drug reaction. Mucosa inflammation (11.5 %), enteritis 
(8.8 %) and immunodeficiency (8.8 %) were further interesting fields of adverse drug 
reaction for patients- Anorexia (0.7 %) and diarrhea (1.4 %) were relevant only for a 
very small part of asked population.  
 
Table 8 Interest of cancer patients in fields of adverse drug reactions (Thoma et al., 
2018). For cancer patients the most interesting field of adverse drug events was nausea. 
 
frequency nausea Mucositis enteritis 
Immuno 
deficiency anorexia diarrhea missing 
        
n = 148 69 17 13 13 1 2 33 
 46.6 % 11.5 % 8,8 % 8.8 % 0.7 % 1.4 % 22.3 % 
 
       
Only 57.4% of cancer patients were satisfied with the information pool about cancer, 
which is illustrated in Table 9.  
 
Table 9 Satisfaction of cancer patients with the information pool about cancer (Thoma 
et al., 2018). About one third of cancer patients was not satisfied with the information 
pool about cancer. 
 
Frequency yes no don't want to answer missing 
     
n = 148  85 (57.4 %) 43 (29.1 %) 15 (10.1 %) 5 (3.4 %) 
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54.1 % of the participants did not use food supplements for therapy completion. 49.3 % 
of the patients declared there has never been an offer regarding food supplements for 
therapy completion, which is illustrated in Figure 12.  
 
 
Figure 12 Assessment of cancer patients regarding the use of food supplements and 
received information about food supplements (Thoma et al., 2018). About half of cancer 




58.8 % of asked population answered to have never received an offer regarding therapy 
linked mental support but almost two third of the patients (60.8 %) thought that mental 
support would be helpful. Likewise, 50.7 % of the asked patients preferred professional 
mental support. 19.6 % of the patients preferred self help groups. These findings are 
illustrated in Figure 13 and Table 10.  
 
 
Figure 13 Estimation of cancer patients regarding reception and usefulness of mental 
support (Thoma et al., 2018). More than half of cancer patients did not receive mental 
support but assessed mental support useful. 
 
Table 10 Cancer patients’ estimation regarding their preferred kind of mental support 
(Thoma et al., 2018). Cancer patients preferred professional support compare to self 
help groups. 
 
 n professional support self help group missing 
        
148 75 (50.7 %) 29 (19.6 %) 44 (29.7 %) 





The findings indicated no significant difference between patients in pharmacy or 
hospital in getting mental support (p=0.600). 31.1 % of the patients in pharmacy 
received mental support. In hospital the ratio was 39.7 %. But in the question "would it 
be helpful" there was significant difference. The pharmacy patients were more positive 
toward mental support (p=0.002). The results are illustrated in Figure 14 and Table 11.  
 
 
Figure 14 Ratio of received mental supply at hospitalized cancer patients and patients in 
public pharmacies (Thoma et al., 2018). Hospitalized cancer patients received more 
mental supply compared to patients in community pharmacies. 
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Table 11 Assessment of helpfulness of mental support at hospitalized cancer patients 
and patients in public pharmacies (Thoma et al., 2018). Compared to hospitalized 











      
 yes no 
don't 
know   
      




(24.6%) yes 0.002 
      
public pharmacy 
n=69 55 (79.7%) 3 (4.3%) 
11 
(15.9%)   
      
a Evaluation with Bonferroni test method. Chi square test was used for categorical 
variables.  
  Fischer exact test was used for border 
values.     
b P value <0.05.      
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There was significant difference in occurred reception of food supplement advice 
between hospitalized patients and patients in public pharmacies (p=0.004). In hospitals 
56.1 % of the patients received food supplement advice. In Town pharmacies the ratio 
of patients which had received food supplement advice was 24.4 %, in village 
pharmacies the ratio was 39.3 %. The results are illustrated in Table 12.  
 
Table 12 Ratio of received food supplement advice at hospitalized cancer patients and 
patients in community pharmacies (Thoma et al., 2018). There was better food 




advice . significance p value a,b 
     
 yes no yes 0.004 
     
hospital n=66 37 (56.1%) 
29 
(43.9%)   
     
town pharmacy n=45 11 (24.4%) 
34 
(75.6%)   
     
village pharmacy 
n=28 11 (39.3%) 
17 
(60.7%)   
     
a Evaluation with Bonferroni test method. Chi square test was used for categorical 
variables.  
Fischer exact test for border values.    
b P value <0.05.     
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5.3 Interview of physicians and pharmacists  
(cf. Thoma et al., 2018) 
 
Pharmacists’ considered interventions to enhance medication adherence and reduce 
drug interactions. Flemings’ research regarding non adherence to prescription 
medication as key factor driving costs in health care systems was already published in 
2008 in the Journal of Managed Care & Specialty Pharmacy (Fleming et al., 2008). 
Home visitation offers especially in countrified areas resulting in ensured supply for 
immobile patients and better pain management were mentioned as well. In eyes of 
pharmacists the use of food supplements gives patients hope and the feeling to 
additionally contribute to their therapy.  
 
Oncologists mentioned the check of sequences or stabilities of cytological treatments as 
interventions to reduce physicians’ workload. Patient admission and residence in 
hospital could have been reduced with a precautionary medication check - up, which 
could have limited costs of national health systems. Oncologists especially emphasized 
expert knowledge. In eyes of physicians this knowledge was in some cases lacking and 
too complex for pharmacists. Physicians considered a main contact person in 
pharmacies as important and necessary to maintain a quick order and delivery process. 
Finally, pharmacists’ interventions regarding pain care were estimated in a positive 
way. In physicians eyes a daily approachable contact person was meaningful for the 
diverse grades of different pain levels in the course of the disease cancer. 
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5.4 Limitations of the results 
 
Consideration of the manuscript in context of several limitations is necessary. The 
subjective definition of inpatient, medium and outpatient care as well as the subjective 
allocation of received results to three groups and the possibility of publication bias, 
outcome reporting bias and bias within included individual studies have to be mentioned 
as weaknesses of my study regarding the results of my literature analysis.  
 
Considering the questionnaire analysis special attention has to be paid to the risk of 
sampling bias. Concerning my unusual results regarding cancer type and gender 
equality in Hungary and Germany one has to consider missing representativeness. These 
data do not define the true national distribution situation and could be provoked by one 
sided selection of distribution places. The excess ob bowel cancer could be not 
randomly influenced by the fact that 71.0 % of Hungarian questionnaires were received 
from hospital. The excess of breast cancer and female cancer patients in Germany could 
be not randomly influenced by a one sided questionnaire distribution in the clinic to a 
department specialised on female cancer diseases. 
 
Moreover the list of agents with an oncology indication in German market contained a 
very broad spectrum of drugs. Therefore, patients with very different states of health 
were included, which resulted in a reduced comparability of patients groups.  
 
Town pharmacies were not categorized precisely. According to our classification a town 
pharmacy could have represented a town with 20,001 inhabitants or a metropolis with 2 
million inhabitants. This could have led to an obtained sample, which was not 
representative of the population intended to be analyzed.   
 
The results were limited to a comparatively small population. The recovery of patients 
was difficult because cancer patients often missed mood or physical constitution to 




The result of this study is limited to the additional use of drugs which could have 
influenced the evaluated QoL results. Furthermore, the study is limited to the type of 
cancer itself affecting the results. The dependence on QoL and cancer type should be 
approached as one of the next steps in the future investigation of cancer patients QoL.  
 
It’s in the nature of things that staff motivation to distribute questionnaires may have 
differed in diverse departments with the result that there could have been reduced 
achievement of proper randomization. Executing staff was asked to address the patients 
and to document successful approaches and failed approaches as well. Since the 
executing staff in pharmacies and hospitals worked only partly in accordance with this 
guideline, the evaluation of the rate of response was not possible. 
 
Even if pharmacy and hospital staff was schooled to elect only patients treated with a 
drug mentioned on the defined list we couldn’t control all the operation modes of 
pharmacy and hospital staff. 
 
Due to the dependence on the voluntary benevolence of the pharmacy owners and even 
more important on the collaboration with pharmaceutical staff in community 
pharmacies and hospitals this study is limited to the number of selected pharmacies and 
hospitals.  
 
Then patients were allowed to take the questionnaire home. There was no possibility to 
control if they received help from family members. It was not possible to force patients 
answering to the questionnaire directly in pharmacy or hospital.  
 
Patients who directly answered in their weekly visited pharmacy could have assessed 
pharmacists in a too positive way, because they would have been uncomfortable with a 
negative assessment.  
 
Just as other studies this research was limited to under reporting of null results and over 
reporting of significant and positive outcomes. Finally, disappeared questionnaires, 
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confounding in hospitals or pharmacies or mistakes during the statistical evaluation 




6.1 Explanation and critical evaluation of results 
6.1.1 Results of literature research 
 
Literature research was performed with the objective of analyzing quantity and utility of 
outpatient models of pharmaceutical cancer care compared to existing interventions of 
pharmacists in hospital or ambulatory oncology settings. In summary existing 
pharmacists’ interventions are of highest quality and have proofed efficacy in all three 
fields of care. I compared the amount of research conducted on pharmacists’ 
intervention approaches in inpatient and medium settings with that in outpatient 
settings; our results show that inpatient and medium models predominate in the 
literature. Nevertheless, a few studies also exist in outpatient fields. Unsurprisingly, 
there are more reported beneficial outcomes associated with inpatient and medium care 
compared with the results of pharmacists’ interventions reportedly associated with 
outpatient oncology care. Altogether the majority of approaches focus on pharmacists’ 
intervention in inpatient and medium care and the section of community pharmacists’ 
interventions in outpatient care remains in big parts unexplored.  
 
This is the first approach who evaluated a little ratio of existing community 
pharmacists’ contributions in outpatient oncology care compared to an excess of 
approaches of pharmacists’ interventions in inpatient and medium oncology care 
(Thoma et al. 2016). 
 
6.1.2 Results of questionnaire research 
 
The questionnaire research was conducted with the objective of analysing need for 
community pharmacists in the daily reality of cancer patients in Hungary and Germany. 
 
Following investigated results underline need for community pharmacists’ interventions 
in cancer care: 
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As human beings grow older and 41.9 % of people fall ill with cancer around the age of 
retirement between 61 and 75 years - shown in Figure 1 - there is need for specialised 
staff. 64.2 % of the patients were diagnosed with cancer not longer than 3 years before 
as shown in Figure 6. Considering the chronic and fatal property of the disease cancer 
there is the necessity of addressing this topic quickest possible with all available 
resources including community pharmacists.  
 
My findings illustrate just if the severe topic is cancer the confidence of patients in 
specialized staff and experts is still high. Regarding the severe topic cancer patients 
want to receive qualified advice. Although internet information could be received faster 
physicians and pharmacists still enjoy a good reputation in the population and therefore 
patients accept waiting times due to their confidence in professionals’ qualified services. 
Table 4 illustrates significant difference p<0.001 in seriousness assessment of internet 
(4.38 ± 2.32) and pharmacists’ information (8.23 ± 1.81).  
 
Validity of pharmacists’ information (8.23 ± 1.81) was assessed almost equal compared 
to practitioners’ information (8.44 ± 1.54) as shown in Figure 8. Probably a purity 
representing white work coat prohibited doubts referring seriousness of a person. The 
digital evolution allowing everyone in the whole world to upload potentially unserious 
information to the internet could have been a further factor for this result (cf. BBC 
2018). Especially cancer patients over 60 preferred information in pharmacies and 
similar at practitioner and oncologist. 35 of 78 patients older than 60 gave the pharmacy 
as preferred information point. These results illustrate demand for eye to eye advice and 
personal relationship between patients and professionals. A many years practiced habit 
could have been casual, too. The acceptance of pharmacists hypothesizes need for 
community pharmacists’ interventions in daily cancer care. 
 
Only 48.6 % of the targeted patient group was able to assess their pain level as shown in 
Figure 9. Probably it is difficult for patients to distinguish between unsustainable pain 
and lighter shapes of pain which impedes right intake of pain killer medications. The 
fact that 39.2 % stated to have difficulties with the right pain killer dosage shows the 
insecurity of patients in this point illustrated in Figure 9. In many cases cancer patients 
receive pain killer treatment in hospital and are discharged with a general medication 
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plan. At home standing on their own it is difficult for many patients to adapt pain killer 
dosage to their temporary requirement. In other cases patients visit several physicians 
and receive several pain killer prescriptions without the knowledge of one physician 
about the prescription of his colleague. This compulsory leads to confusion and 
subsequently a worse adjusted pain level of cancer patients. It is one of community 
pharmacists’ ordinary tasks to help patients reducing their pain level by giving 
professional advice referring adequate drug intake. Additionally, it is not enforceable to 
meet oncologists or physicians weekly and not to mention daily. Therefore, community 
pharmacists’ skills appear as promising alternative to help patients adjusting their pain 
killer dosage. 
 
Due to the fact that almost half of cancer patients used pain killers and pain is a factor 
with high influence on patients’ level of quality of life this topic is important for cancer 
patients which deserve to live as good as possible their remaining life time. 
Nevertheless, one has to take the statement of the WHO into account that cancer 
patients’ perception of QoL depends not only on disease- and treatment-related factors 
but also on social relationships and individual value systems in relation to individual 
expectations and standards (World health organization, 2017; Singer et al., 2013). In the 
end of the questionnaire patients had the possibility to answer to an open question and 
state their wishes and expectations. The most important point for patients was to have 
persons they can talk to – medically and primarily from human perspective. Community 
pharmacists own this social potential and could give patients the feeling of importance 
and consequently an increased level of life quality in their remaining life time.  
 
On a scale from 1 to 100 the investigated level of quality of life was in Hungary 65.91 ± 
19.24 and in Germany 57.35 ± 23.44 as illustrated in Tables 6 and 7. Considering these 
results and above mentioned patients’ expectations increase of patients’ level of quality 
of life in case of intensified use of community pharmacists in cancer care could be 
hypothesized. The relevance of the topic quality of life for the assessment of community 
pharmacists’ use in cancer care has to be assessed under consideration that this 
hypothesis has not proofed final evidence. 
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8.8 % of patients treated with anticancer therapies were not informed about possible 
occurring adverse drug reactions as shown in Figure 11. Only 57.4 % of asked patients 
were satisfied with the received information about adverse drug reactions as illustrated 
in Table 9. Referring the fields of adverse drug reactions patients were mostly interested 
in nausea (46.6 %) und mucosa inflammation (11.5 %) as shown in Table 8. The result 
hypothesize in most cases there is no need for exotic advice but rather for basic 
counselling services of professional staff like community pharmacists. I can confirm by 
first hand experience in my pharmacy the benefit and gratefulness of patients receiving 
detailed instructions regarding their drug intake. 
 
49.3 % of the asked patients declared there had never been an offer regarding food 
supplement advice as shown in Figure 12. According to my opinion every patient has 
the right to be informed about existing possibilities of additional therapy approaches. 
Therefore, not only the enhancement of adverse drug reactions clearing up but also the 
break of prospective approaches regarding food supplement advice to patients are 
possible achievements of community pharmacists in cancer care. 
 
58.8 % of the patients never received therapy linked mental support but 60.8 % thought 
it would be helpful as illustrated in Figure 13. More than two third preferred 
professionals compared to self help groups as shown in Table 10. Figure 14 and Table 
11 illustrate that pharmacy patients were more positive toward mental support compared 
to hospitalized patients (p=0.002). In hospital in many cases patients were in a position 
of end stage. Perhaps they even wanted to think about mental support and had little hope 
left. The often long lasting personal relationship between patients and their community 
pharmacist could have led to a stronger confidence of patients in community 
pharmacists. The fact that patients have stronger confidence in professionals than in self 
help groups underlines the necessity of professional experts. In many cases patients are 
lonesome at home and pharmacists are the first contact person for patients’ problems – 
including mental issues. Community pharmacists’ position implicating the meeting of 
patients almost daily emerged as an important characteristic to assess patients’ 
emotional state, which allows pharmacists to act as kind of mediator between patients 
and professionals in mental support.  
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Compared to town pharmacies (24.4 %) and village pharmacies (39.3 %) in hospital 
(56.1 %) there was more reception of food supplement advice as illustrated in Table 12. 
Additionally, in hospital (52.3 %) there was better coordination of pain killer intake 
compared to town pharmacies (20.0 %) and village pharmacies (43.8 %) as shown in 
Table 5. For adequate pain management continuance and a certain time period of 
contact with the patient is advantageous. In this point the capabilities for comprehensive 
supply are better in hospital. In hospital there was assistance round the clock. Clinical 
pharmacists held expert knowledge and patients were able to ask for food supplement 
advice or pain killer adjustments whenever they wanted. The beneficial roles of clinical 
pharmacists regarding individual nutrition counselling services were already reported 
(Tuffaha et al., 2012; Mousavi et al., 2013). In contrast outpatient cancer patients often 
are alone at home, the walk to the pharmacy is in many cases burdensome and therefore 
many emerging questions disappear. For those patients intensified interventions of 
community pharmacists and innovative approaches for home care services are of 
exceptional value. 
 
In the introduction part I described that the incentive of this PhD thesis was the meeting 
of cancer patients in my pharmacy with insufficient knowledge about their medication. 
The considerations of this chapter highlight the need for community pharmacists in the 
daily reality of cancer patients. Providing integration and collaboration with community 
pharmacists as basic condition, pharmaceutical care can have an important share in 
future cancer care. 
 
6.1.3 Results of health experts interviews 
 
Interviews were conducted with the objective of receiving the opinion of health experts 
to community pharmacists’ use in cancer care. 
 
Both pharmacists and oncologists thought that in many cases patients could take profit 
from better coordination between health experts but there is a communication problem 
between pharmacists and physicians. Pharmacists mentioned home visitation offers and 
food supplement advice as important approaches. Oncologists emphasized the check of 
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cytotoxical treatments. Both expert groups considered detailed schooling of pharmacists 
in special fields of oncology as the most important point to maintain expert knowledge. 
Nevertheless, physicians still want to avoid limitations of their own skills and their 
therapeutic freedom. In contrast pharmacists battle the fame of the small brother besides 
physicians to be accepted as equated professional in health care.  
 
Finally, considering community pharmacists’ support in oncology care I am the first 
who matched a comprehensive research of existing pharmacists’ interventions in 
literature, a patient reported questionnaire analysis in Hungary and Germany and a 
professional directed health experts’ interview (Thoma et al., 2018) 
 
6.2 Vision  
6.2.1 Cancer care in the digital age 
 
The term Digital Health will play a major role in future cancer care. The digital progress 
becomes quicker and quicker and a conflation between information technique and 
medicine is observable for several years. The advanced digital revolution since the turn 
of the millennium offers new possibilities of networking which allow the documented 
and clustered contribution of several experts to the therapy strategy of one patient. The 
digital revolution is at the same pitch as inventions like antibiotics or x-rays. 100 years 
ago nobody was able to imagine cardiac pacemakers. Now this is part of the standard 
operations in almost each bigger hospital. High technology not only enhances the way 
of documenting and transporting information but also influences cancer treatments in a 
direct way. High laser technique enables precise radiation of tumour cells without 
damaging surrounding tissues.  
 
The new way of data transfer e.g. with electronic health cards allows the transmission of 
already imposed patient data without the loss of knowledge on the way from one expert 
to another. The electronic health card will be the next step in the German health system 
to consolidate the whole current patient medication received by physicians’ prescription 
and at the recommendation of pharmacies. Thereby it could be easier for future studies 
to identify cancer patients’ total medication. Sooner or later also electronic prescriptions 
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will replace the classical prescriptions on paper which promises faster processing and 
protection against forgery.  
 
Today in medical practices in many cases lab data are still existent disordered and in 
hardcopy form. Often physicians view only the patient in front of them and act from the 
basis of their own experience. Considering the global burden of cancer adduction of 
clinical data of millions of cancer patients has to be intensified for diagnosis and therapy 
forms.  Therefore, not only acquisition of data but also digital documentation and better 
classification in homogenous databases has to be intensified. Unburdened access from 
all areas of the world to those databases has to be forced. The connection of huge data 
pools is challenging but convertible with existing and further developing possibilities of 
digital information techniques. Besides taking care of patients and giving advice it will 
become a physicians’ main task to create and document health knowledge which can be 
used by everyone in the whole world. If physicians daily contacted with patients 
intensify the documentation of their daily experiences and perceptions the huge pool of 
health information would not only be limited to theoretical scientific research but would 
also be extended with practical information. The combination of these two issues could 
render health knowledge of the human race more powerful.  
 
There also are approaches of telemedicine offering patients video counselling services 
of physicians. According to my opinion one should try to use the beneficial digital 
possibilities but one should avoid the constrained overturn of the well established 
relationship of patients and professionals. There is no digital possibility which is able to 
substitute physical eye to eye advice permitting empathic interpretation of patients’ 
physical and psychical conditions. Professionals still have to be able to touch patients 
for comprehensive perception of their needs. 
 
Despite of above mentioned advantages the digital period is limited and exhibits 
disadvantages, too. The incidents in May 2017 in Great Britain show the vulnerability 
of the connected global world. Nobody considered a hacker attack possible which 




such a global blackout supply of millions of patients could be deficient with 
unpredictable consequences.  
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New approaches referring diagnosis and therapy in cancer care 
 
A footrace between human advancements and adaptation processes of cancer cells is 
presumably. Similarly to bacterial cells it will become important who of the 
counterparts is a step ahead. Therefore, not only innovative therapy strategies but also 
new approaches of cancer diagnosis will be essential to identify reasons for the specific 
genesis of cancer.  
 
Even if the tumour cells quickly expand malignant cells consistently die and emit DNA 
fragments into the blood stream. This fact is known for quite some time but the methods 
of reliable verification procedures have become better and better the past years. There 
are promising approaches especially regarding lung cancer to identify such DNA 
fragments in the blood stream of patients. Using such methods health experts could be 
able to diagnose cancer by taking blood samples instead of biopsies (Zhao et al., 2018; 
Han et al., 2017). 
 
Thereby the amount of early detected cancer diseases could rise in future because of the 
simple and gentle method. Even now day to day millions of blood samples are routinely 
taken in the global world. It remains the secret of the future if cancer diseases can be 
detected some day by standardized blood tests. Analyzing the amounts of DNA 
fragments in the blood stream could be a step to limit the expansion of the disease 
cancer at the earliest possible stage. 
 
Similarly to the so called metabolic syndrome at cardiovascular diseases it will be 
essential to recognize cancer risk factors. It is known that high blood pressure, diabetes, 
obesity and disruptions of the lipid metabolism are considered as main risk factors for 
falling ill with cardiovascular diseases. Detailed identification of cancer risk factors will 
be essential to be able to preclude cancer with preventive activities. 
 
Using the experience values of above mentioned databases development of more 
efficient personalized therapy forms could be enabled. Down to the present date cancer 
patients’ therapy response is still a big problem. Even if cancer type, cancer stadium and 
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patient characteristics are very similar there are big differences regarding the response 
to equal therapies. Referring to personalized therapy forms immunotherapy is a 
promising approach and has to be refined in future. Investigators try to analyse specific 
targets on tumour cells of the individual cancer patients and then try to activate the 
immune system of the patients to attack this target (American cancer society, 2018). Of 
course this technology is still in its infancy but besides the hoped better response of 
cancer patients to the treatment this kind of technology could provide cost efficiency. 
 
From financial perspective one can imagine that it is more expensive to try three or four 
different cytotoxic therapy strategies and then has to assert that the patient has 
responded to none of those than treating patients with personalized high effective 
therapy forms (cf. Ventola et al., 2017). Considering such future approaches perhaps it 
could be no exceptional case if a human being becomes 100 years old. It remains to be 
seen and an ethical question if this is required generally. 
 
6.2.2 Increasing cancer rates and personal shortage 
 
The amount of cancer rise with increased age and the demographic development 
proceeds. This combination constitutes a vicious circle which is difficult to burst. 
Progressing financial and especially personal shortage will contribute to the strained 
situation in cancer care. Not only the general increase of cancer patients, but also the 
rising shortage of physicians poses a very difficult context. There are too many 
physicians aged 60+ and too little renewable young physicians. 
 
Additionally, life is getting fast moving more and more, the human being suffers from a 
lack of time and therefore patients will decreasingly accept waiting times for medical 
specialists of one month or longer. Especially in countrified areas the distances between 
patient and the next physician will become larger.  
 
For young human beings the job physician is no longer the dream job par excellence 
which is also visible in hospitals. Not only emergency services in countrified areas 
linked with particularly required accessibility round the clock, but also emergency 
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services in hospitals are associated with often understaffed working hours and bad 
payment. Especially prospective physicians in education arriving after university in 
hospital are confronted with adverse conditions. The graduation to a medical specialist 
often takes time with the consequence that finished medical specialists are often aged 35 
to 45. Hence from the financial perspective even with the earnings of medical specialists 
it is difficult to counterbalance in the remaining man years the lead of persons which 
have begun working at the age of 15. 
 
Then the past years a change of young people mindset is cognizable. The so called   
Work Life Balance becomes more and more important for young human beings. Many 
well educated and promising high school graduates consciously abstain from financial 
and career interests but gain a working life with little time pressure and free times from 
Friday midday to Monday.  
 
All above mentioned issues contribute to the overload and a shortage of physicians in 
cancer care. Finally, especially in cancer care the enhancement of therapy strategies 
have led to life extension of patients (Lucke et al., 2010). Formerly patients would have 
simply died earlier, which also constitutes additional workload for physicians.  
 
Therefore, in Germany politics even subsidises physicians in countrified areas with high 
amounts of money if they transfer their point of retirement from the age of 60 to the age 
of 70. Additionally, there are approaches, which facilitate access to the academic studies 
of medicine for high school graduates which achieved worse grade point averages but 
obligate themselves to at least 10 year lasting employments as physician in countrified 
areas. A greater extent of such approaches will be necessary to maintain specialised 
staff, comprehensive supply of patients and finally the limitation of cancer spreading. 
 
6.2.3 The role of pharmaceutical care in future oncology care 
 
Cancer care will be a central topic for pharmacists in the next decade. Considering the 
personal shortage it will be important to provide specific, research-based direction for 
implementing community pharmacists with their skills as health care professionals in 
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oncology care.  For that purpose the standardized integration of pharmacists in medical 
teams will be essential to reduce the burden of physicians and oncologists workload.  
 
This can only work if both pharmacists and physicians are able to talk on eye level and 
respect each other as equal members in the common fight against cancer. Considering 
the possibilities of the digital age the integration of several health experts in the medical 
team is much easier than in the past and presents no longer a problem.Since March 2017 
in Germany the legal access to cannabis is facilitated. Cannabis is expected to help 
some of the cancer patients tolerating pain symptoms better than usual pain killers. 
Cannabis preparations are available as oily drops which alleviate accurate dose 
adaptation. In Germany the ultimate fabrication of these oily drops is task of community 
pharmacies. Hence a first step of community pharmacists’ integration in oncology care 
has already happened.  
 
Considering the chronic and ruthless properties of the disease cancer all experts 
conform that preserving of QoL is the minimum to do for cancer patients. It is the 
responsibility of all involved parties including pharmacists to arrange the everyday life 
of cancer patients as normal as possible and to consequently preserve cancer patients’ 
level of QoL. For many cancer patients the main parameter deciding the level of QoL is 
pain. Since all cancer types can be longer fatal it will be of importance to develop 
strategies which attenuate cancer patients’ pain to a tolerable level.  
 
Patients’ wishes regarding eye to eye advice and a personal relationship between 
patients and professionals will have to be emphasized. Time for this desire is lacking at 
physicians and especially in oncology care. Community pharmacists’ skills are capable 
of shortening this lack – qualified and with an adequate time schedule. Therefore, 
community pharmacists will be required to execute precautionary medication check ups, 
and to counsel cancer patients regarding food supplements and coordination of pain 
level and adequate pain killer intake. Additionally, community pharmacists’ will have to 
focus their social potential, which could avoid patients’ loss of social integration in the 
community and give patients the feeling of importance and subsequently an increased 
level of quality of life in their remaining life time. Furthermore, community pharmacies 
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will have to develop new fields of actions such as home visitations. Those services 
provide local community pharmacies the opportunity of an additional source of income 
to stand up to the online pharmacies crowding in the market with dumping prices. 
Compared to online pharmacies only the local community pharmacists are able to 
execute contemporary home visitations. In times of financial shortage of national health 
systems there is less hope that health insurances will pay this service. It remains to be 
seen if patients are able and willing to pay such services privately.  
 
Besides the efforts regarding community pharmacists’ contribution to oncology care a 
continuous enhancement of already existing and beneficial approaches of pharmacists’ 
intervention in inpatient and medium care may not be neglected. Presuming further 
education referring to expert knowledge in oncology care pharmacists can improve the 
efficacy of inpatient care in several ways. Patient directed counselling services guided 
by a main pharmacist are time intensive but hypothesize enhanced medication 
adherence and subsequently lower amounts of ADE’s.  Not only in community 
pharmacies but also in inpatient and medium care main contact persons will be essential 
to organize and collocate the diverse working procedures. As member of the medical 
teams pharmacists will be able to directly prevent ADE’s in the framework of a 
medication check up and indirectly reduce physicians’ workload.  
 
In medium care patient focused approaches will emerge similarly to above mentioned 
services of pharmacists in inpatient care. It could become a task of pharmacists to 
alleviate patients the transition from hospital home or from home to hospital. Due to the 
physical and psychical constitution of cancer patients the involvement of family 
members will play a major role. On the one hand, patients confide in family members 
and on the other hand those people are cancer patients first contact persons at home. 
Pharmacists are able to retrace the medical history with their expert knowledge from the 
professional perspective. It should become pharmacists’ task to convey this information 
in a comprehensible way to cancer patients’ family members. Hospital admissions often 
very quickly after the last hospital release could be prevented with such clearing up 




The driving force of my project was the hope that my findings give a base for the 
discovery of future approaches, which limit the escalating problem cancer and allow 
positive influence on the supply of next generation cancer patients. To stay in reality by 
reason of the diverse, quick changing and different proceeding types of cancer the big 
breakthrough which erases the disease cancer is unlikely. Nevertheless, I feel confident 
that contributions of pharmacists to cancer patients’ supply could be a little brick to get 
a grip on the expanding problem cancer in future.  
 
Finally, the results of the dissertation have to be examined under consideration of the 
following issues. 
 
Finally, the author of the dissertation is pharmacist which may have biased the 
unconscious interpretation of the answers. 
 
There were a comparably small number of questionnaire participants. Therefore, further 
research should be conducted addressing a larger target population. 
 
The setting of the distributed’ questionnaire and the questions used for professional 
health experts’ interview includes an unexpressed but sensible preconception that there 
is a need for pharmacists’ intervention, which could bias the later questionnaire 
answers. Therefore future research should be conducted using modified questionnaires, 
divided in two arms for participants confirming need for pharmacists’ interventions and 





To contain the expansion of cancer it will be necessary to focus all disposable human 
and technical forces of the human race. My findings proofed great demand and 
usefulness of pharmacists’ interventions in cancer reality and highlighted still room for 
intensified research engagement into community pharmacists’ unspent skills in 
literature. My study gives an overall view of existing literature regarding quantity and 
utility of pharmacists’ interventions in all fields of oncology care and compares the 
received results with patients and professionals needs in cancer reality of two European 
countries.  
 
In literature analysis I investigated many approaches in inpatient, medium, and — 
By means of the cross-national questionnaire analysis I collected comprehensive 
information from substantial participants of cancer care in two European countries to 
estimate community pharmacists’ use in present cancer care. The questionnaire analysis 
and the interview of professional health experts helped me determine the extent to 
which interventions reported in the literature correlate with patients’ and experts needs 
in cancer reality. Considering performed questionnaire analysis and conducted 
interviews with professionals the big majority of outcomes showed demand and 
usefulness of community pharmacists’ support in cancer reality.  
 
Both patients and professionals are open minded to further approaches of community 
pharmacists’ interventions, such as home care services, medication Check-ups or 
assistance regarding mental supply. The control of adverse drug reactions and drug 
interactions has to be one of pharmacists’ main tasks to avoid hospital admissions and 
subsequently reduce costs for health care system.  
 
There is need for pharmacist guided pain management models for better symptom 
control in palliative care. A certain contact person in each pharmacy is important to 
ensure better communication and discussions on eye level with general practitioners and 
physicians in hospital. Based on my findings I believe that further investigation into 
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quantity and utility of community pharmacists’ interventions is essential in present 
cancer care.  
 
To give powerful guidance for the future equal communication between physicians and 
pharmacists on eye level, integration of community pharmacists in oncology outpatient 
assistance and of capital importance schooling of community pharmacists in special 
fields of oncology care have to be mentioned as only three possibilities to maintain 
expert knowledge, reduce physicians’ workload, limit costs of national health systems 
and in conclusion enhance cancer patients supply. 
 
This PhD thesis could be the basis for further approaches. It remains to be seen if and to 
what extent community pharmacists’ contribution will find a way into oncology care.  
 
7.1 Novelty of the thesis 
 
 Considering community pharmacists’ support in oncology care I am the first who 
matched a comprehensive research of existing pharmacists’ interventions in 
literature, a patient reported questionnaire analysis in Hungary and Germany and 
a professional directed health experts’ interview. 
 
 This is the first approach who evaluated the little ratio of existing community 
pharmacists’ contributions in outpatient oncology care compared to an excess of 
approaches of pharmacists’ interventions in inpatient and medium oncology 
care.  
 
 There is no other approach in this modality which discovered a reverse 
correlation of a shortage of investigation efforts into community pharmacists’ 
interventions in literature and rising demand and usefulness of community 
pharmacists’ interventions in cancer patients’ reality. 
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7.2 Practical relevance of the thesis 
 
 To limit cancer the quickest spreading disease down to the present date it is 
mandatory to develop new approaches and exhaust all available human and 
technical resources.  
 
 Considering personal and financial shortages national health systems may not 
exclude the qualified and little used resource community pharmacists. 
 
 It is important to develop new strategies regarding cancer patients QoL because 
cancer is a disease which rapidly leads to death and often many cancer patients 
have little time left in their remaining life time. 
 
 On a variety of grounds community pharmacists’ integration in oncology care is 
useful for cancer patients QoL. 
 
o Evaluation of cancer patients’ QoL showed still room for improvement of 
cancer patients’ QoL.  
 
o The most important point for cancer patients was to have persons they can 
talk to – medically, from human perspective and with an adequate time 
schedule.  
 
o  The social and pharmaceutical potential of community pharmacists is 
able to cope with those needs. 
 
o Physicians and patients are open towards community pharmacists’ 
interventions in cancer care. 
 
 The almost weekly visit of cancer patients in the pharmacy could be used for 




o About 50 % of the examined patient population are not able to assess their 
pain level. 
o Only one fourth of the examined patient population stated to be able to 
coordinate pain level and right pain killer dosage. 
 
 By first - hand experience I can confirm cancer patients’ demand for specialized 
pharmaceutical care. 
 
o In my pharmacy cancer patients appear daily with insufficient knowledge 
about intake, effects and consequences of highly effective drugs. 
 
o Two third of the examined patient population had experiences with 
ADE’s. 
 
o Less than 60 % of the examined patient population was satisfied with the 
current information pool regarding ADE’s.  
 
 Intensified clearing up about risks of smoking is necessary.  
 
 There are accumulated needs in community pharmacies regarding food 
supplement advice. 
 
o About the half of the examined patient population was not informed about 
food supplements for therapy completion. 
 
o Food supplement advice in hospital was better compared to community 
pharmacies. 
 
 There is need for intensified mental support for cancer patients, because only one 
third of the examined patient population received mental support, but two third 




 The weekly visited community pharmacists can operate as mediator between 
cancer patients and professional experts in mental support. Patients, who 
received the questionnaire in public pharmacies were more positive towards 
mental support than hospitalized patients. 
 
o Professional experts in mental support were preferred by the examined 
patient population compared to self - help groups. 
 
 As opposed to internet information the examined patient population had 
confidence in the validity of pharmacies as first information points in always the 
same manner than in practitioner information. 
 
 All above mentioned results indicate great demand and usefulness of community 
pharmacists in cancer reality.  
 
 Integration of community pharmacists’ in oncology care has to be encouraged.  
 
 Increased schooling of community pharmacists in special fields of oncology care 
and talking on eye level between physicians and pharmacists provide a basis to 





Cancer is on the fast lane and could replace cardiovascular diseases as the most 
common cause of human death in future. In face of this expanding problem national 
health systems struggle with less human and financial resources. There is a growing risk 
that these contrary points will gape apart onwards in future. I tried to explore if 
pharmacists can contribute to the containment of this escalating problem. I analysed 
incident and extent of scientific research regarding pharmaceutical contributions in 
oncology care. Thereby I was able to classify existing approaches in literature and got 
an overview of current supply of cancer patients. Additionally, I explored community 
pharmacists’ use in present cancer care with a self - developed closed ended 
questionnaire distributed to cancer patients in hospitals, town pharmacies and village 
pharmacies of Hungary and Germany and interviewed professionals of health care. 
Thereby I analysed cancer patients’ situation and needs and received a picture of 
essential requirements from pharmacists in the daily reality of cancer patients and 
professionals. My findings show great demand and usefulness of community 
pharmacists in oncology care. In summary I performed a broad literature research and 
collected comprehensive information from substantial participants of cancer care in two 
European countries to estimate community pharmacists’ use in present cancer care. 
Within the framework of my PhD thesis I was the first who matched literature research 
and reality analysis of community pharmacists’ contributions to oncology care in 
Hungary and Germany. The comparison of these two projects resulted in the discovery 
of a reverse correlation between an untended issue in scientific literature and great 
requirements for pharmaceutical support in oncology reality. The results of my PhD 
thesis should be the basis for further investigations and a better use of unspent resources 





A rosszindulatú daganatos megbetegedések a jövőben várhatóan a leggyakoribb 
halálozási okot jelentik, megelőzve a kardiovaszkuláris kórképek okozta halálozást. A 
nemzeti egészségügyi rendszereknek az egyre növekvő problémával szemben egyre 
kevesebb emberi és pénzügyi erőforrással kell megküzdeniük. Fokozottan fennáll annak 
a kockázata, hogy ezek az egymás ellenében ható tendenciák a jövőben még 
kifejezettebbek lesznek. Doktori munkám során célul tűztem ki annak a feltárását, hogy 
a gyógyszerészek hozzájárulhatnak-e ennek a növekvő problémának a mérsékléséhez. 
Szisztematikus irodalomelemzést végeztem, hogy képet kapjak az onkológiai ellátással 
kapcsolatos gyógyszerészi szerepvállalás módjairól és azok mértékéről1. Így a 
szakirodalomban fellelhető módszereket osztályoztam, és áttekintettem a daganatos 
betegek jelenlegi ellátását. Emellett kórházakban, magyar és németországi városi és 
kistelepülési gyógyszertárakban egy saját fejlesztésű, zárt kérdésekből álló kérdőíves 
felmérést végeztem onkológiai betegek körében, hogy a közforgalmú gyógyszerészek 
jelenlegi szerepét vizsgáljam az onkológiai betegek ellátásában, valamint a témában 
interjút készítettem egészségügyi szakemberekkel2. Elemeztem az onkológiai betegek 
helyzetét és szükségleteit, és képet kaptam a gyógyszerészekkel szemben támasztott 
elvárásokról. Eredményeim megerősítik, hogy a közforgalmú gyógyszerészi gondozás 
iránt jelentős igény van az onkológiai ellátás területén is. Összefoglalva, széleskörű 
szakirodalmi kutatást végeztem és átfogó információt gyűjtöttem az onkológiai betegek 
ellátásának résztvevőiről két Európai Uniós országban, azzal a céllal, hogy felmérjem a 
közforgalmú gyógyszerészek alkalmazását a jelenlegi onkológiai ellátás gyakorlatában. 
Doktori értekezésem keretében elsőként hasonlítottam össze az irodalmi adatokat a 
magyar és német közforgalmú gyógyszerészek onkológiai ellátásban betöltött valós 
szerepével. A két projekt összehasonlításának eredményeként fordított összefüggést 
találtam a tudományos szakirodalomban elhanyagolt gyógyszerészi szerep és az 
onkológiai betegek gyógyszerészi gondozásának igénye között3. Doktori értekezésem 
eredményei további vizsgálatok alapját, valamint a nemzeti egészségügyi rendszerek 
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Dear patient, my name is Johannes Thoma and I am pharmacist. I want to make 
contribution to enhancement of cross national pharmaceutical support of cancer therapy 
in Europe. Therefore, the following questionnaire was designed. It would be nice if you 
could find a few minutes two respond to these questions for enabling better 





Study cover: Patient desire for more pharmaceutical support during process of 
cancer therapy. 
 







- Patients will be asked to answer these questionnaire, if they get any agent 
mentioned in annexed list 
- Pharmacists are not allowed to help patients, if there arise any questions 





- The questionnaire will be distributed in Germany and Hungary. In each case 
two hospitals as well as 10 village and 3 town pharmacies will be chosen for 
distribution. 
 
- Pharmacists have to note down number of tries and success, when asking 
patients to answer to these questions  
 
- Pharmacists respectively clinical staff should work towards filling out 
questionnaire in pharmacy respectively hospital in order to raise up quantity 
of returned questionnaires 
 
Declaration of confidentiality: The questionnaire is anonymous. All received data will 










Please select only one predetermined answer of each question. Otherwise this question 
is invalid and cannot be evaluated. 
 
 
1. Which gender do you have? 
 
male:      female:  
 
2. How old are you? 
 
18-30   31-45   46-60   61-75  75+  
 
Where did you receive this questionnaire? 
 
town pharmacy  village pharmacy   hospital centre  
 
3. Which type of cancer do you have? 
 
breast cancer   prostate cancer  lung cancer  
   
stomach cancer   pancreatic cancer    bowel cancer   
 
cerebral cancer     
 





4. How long is the period of time since diagnosis? 
 
1-3 years   4-6 years   7-10 years  more 10 years  
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5. Which education level do you have? 
basic school    secondary school   grammar school  
 
  university degree   don’t want to answer   
 
6. Do or did you smoke? 
 
Yes      No    don’t want to answer  
 





7. Smoking can be a starting point for falling ill with cancer! Please estimate how 
much you agree with this statement? 




8. If you want to get information about cancer in general, what is your first 
information point? 
 
 familiy   internet   general practitioner  
 
 neighbourhood  pharmacist   television   
 
 friends  oncologist  
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9.  Please assess the validity of first information resource by marking with a cross 
on a scale from 1 - 10? 
 
(1 = less validity; 10 = strong validity) 
 
 family  1-------2-------3-------4-------5-------6-------7-------8-------9-------10 
 
 internet 1-------2-------3-------4-------5-------6-------7-------8-------9-------10 
 
 general practitioner 1-------2-------3-------4-------5-------6-------7-------8- 
------9-------10 
 
 neighbourhood 1-------2-------3-------4-------5-------6-------7-------8-- 
---9-------10 
 
 pharmacist 1-------2-------3-------4-------5-------6-------7-------8-------9-------10 
 
 television 1-------2-------3-------4-------5-------6-------7-------8-------9-------10 
 
 friends 1-------2-------3-------4-------5-------6-------7-------8-------9-------10 
 







10. Are you satisfied with your pool of information? 
 
 Yes    No     don't know  
 
If not, what would you expect to get the situation improved? 
 
There are a few statements below, please assess, how much you would agree? 
(1 = don't agree, 5 = fully agree) 
 
 detailed websites for cancer patients  1-------2-------3-------4-------5 
 
 better communication within social environment  1-------2-------3-------4-------5 
 
 special consultation offers in pharmacies  1-------2-------3-------4-------5 
 
 special broadcast program on television  1-------2-------3-------4-------5 
 
 consultation during practitioner visitation  1-------2-------3-------4-------5 
 
  Have you ever had side effects during cancer treatment? 
 
 Yes    No  
 
If yes, before you had side effects, did anyone inform you about typical possible 
adverse reactions? 
 
 Yes    No  
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11. In which fields of typical adverse drug reactions would you expect to get more 
information before treatment? (You can make more then one mark) 
 
 nausea     mucositis    enteritis   
 
 immunodeficiency    anorexia    diarrhoea   
 
 any other ........................................................ 
 
12. Did you ever be informed about food supplements for cancer therapy 
completion especially according to reduce side effects and interdependencies in 
your drug medication? 
 
 Yes      No  
 
If yes, what was your information resource? 
 
 pharmacist    magazines    practitioner  
    
 internet    social environment  television  
 
13. Are you satisfied with your pool of information? 
 
 Yes      No    don't know  
 
If not, what would you expect to get better information?  
There are a few statements below, please assess, how much you would agree? 
(1 = don't agree, 5 = fully agree) 
 
 detailed websites for food supplement information  1-------2-------3-------4-------5 
 
 better communication within social environment 1-------2-------3-------4-------5 
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 special consultation offers in pharmacies  1-------2-------3-------4-------5 
 
 special broadcast program on television  1-------2-------3-------4-------5 
 
 consultation during practitioner visitation  1-------2-------3-------4-------5 
 
14. Do you already use food supplements for therapy completion? 
 
 Yes      No  
 





15. Have you ever got any mental support according to handle the psychic situation 
during cancer treament? 
 
Yes      No     don’t know  
 
16. Would it be helpful to get any mediation for mental support? 
 
Yes      No     don’t know  
 
If yes, which kind of support would you prefer? 
 
 professional mental support     self help group   
 
  any other ............................................. 
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17. Have you ever had pain due to your cancer? 
 
 Yes      No  
If yes, do you think, you can estimate your level of pain? 
 
 Yes      No   
 
If, yes, please categorise your pain level on a scale from 1 to 10? 
(1 = no pain, 10 = maximum pain) 
 1-------2-------3-------4-------5-------6-------7-------8-------9-------10 
 
18. Does your drug medication include pain killers? 
 
 Yes      No   
 




Do you think you can coordinate current pain level and right dosage of pain 
killers? 
 
Yes      No  
 
19. Have you ever had any analysis about your quality of life conditions? 
 
Yes      No  
 
20. Do you think you can estimate your current quality of life? 
 
Yes      No  
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If yes, please estimate your current level of quality of life on a scale from 1% - 100%!  




What would you expect from pharmacists to raise up your quality of life 



























3. Years of practice: 
 
4. Type of exercise 
 
Is there according to our opinion need for pharmacists’ intervention in oncology care? 
 
 
If yes please specify from your position why and please specify the intervention: 
 
 
If no please specify why not: 
 
 
Please try to get into patients’ mind. Which advantages/ disadvantages of pharmacists’ 
interventions are reasonable? 
 
Do you think pharmacists are ready to do so? 
 
Which main obstacles do you imagine? 
 
How would you climb this cliff? Which solutions are reasonable? 
DOI:10.14753/SE.2019.2307
104 









Doxorubicin L01DB01 Azathioprin L04AX01 Glatirameracetat L03AX13 
Tacrolimus L04AD02 
BCG - 
Vaccine L03AX03 Daunorubicin L01DB02 
Cytarabin L01BC01 
Interferon 
beta 1b L03AB08 Triptorelin L02AE04 
Pemetrexed L01BA04 Bicalutamid L02BB03 Gemcitabin L01BC05 
Anastrozol L02BG03 Temozolamid L01AX03 Methotrexat L01BA01 
Nilutamid L02BB02 Bleomycin L01DC01 INF alpha natur L03AB01 
Leflunomid L04AA13 Carboplatin L01XA02 Leuprorelin L02AE02 
Exemestan L02BG06 Docetaxel L01CD02 Oxaliplatin L01XA03 
Nelarabin L01BB07 Irinotecan L01XX19 Etanercept L04AB01 
Bevacizumab L01XC07 
Mycophenol 
acid L04AA06 Epirubicin L01DB03 
Interferon 
beta 1a L03AB07 Everolimus L04AA18 Cetixumab L01XC06 
Bortezomib L01XX32 
Certolizumab 
pegol L04AB05 Estramustin L01XX11 
Vinblastin L01CA01 Cisplatin L01XA01 Etoposid L01CB01 
Vincristin L01CA02 Verteporfin L01XD02 Capecitabin L01BC06 
Filgrastim L03AA02 Aldesleukin L03AC01 Golimumab L04AB06 
Abatacept L04AA24 Sirolimus L04AA10 Basiliximab L04AC02 
Paclitaxel L01CD01 Infliximab L04AB02 Goserelin L02AE03 
Peginterferon 
alpha 2a L03AB11 Tocilizumab L04AC07 Ciclosporin L04AD01 
Peginterferon 
alpha 2b L03AB10 
Interferon 
alpha 2a L03AB04 Natalizumab L04AA23 
Panitumumab L01XC08 Temsirolimus L01XE09 Idarubicin L01DB06 
Letrozol L02BG04 Topotecan L01XX17 Dasatinib L01XE06 
Cefarabin L01BG06 
Interferon 
alpha 2b L03AB05 Ustekinumab L04AC05 
Interferon 
beta 1b L03AB08 Gefitinib L01XE02 Buserelin L02AE01 
Toremifen L02BA02 
Carbamid-
OH L01XX05 Sunitinib L01XE04 
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Fulvestrant L02BA03 Mitotan L01XX23 Lepatinib L01XE07 
Degarelix L02BX03 Alemtuzumab L01XC04 Tamoxifen L02BA01 
Fludarabin L01BB05 Rituximab L01XZ02 Erlotinib L01XE03 
Fluoruracil L01BC02 Megestrol L02AB01 Nilotinib L01XE08 
Flutamid L02BB01 Plerixafor L03AX17 
Tegafur, 
combinations L01BC53 
Tegafur L01BC03 Fotemustin L01AD05 Anagrelid L01XX55 
Imatinib L01XE01 Vinorelbin L01CA04 Ralitrexed L01BA03 
Trastuzumab L01XC03 Pegfilgrastim L03AA13 Adalimumab L04AB04 
Sorafenib L01XE05     
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